Shift in biosimilar commercial landscape essential for sector sustainability, expert says - Pharmaceutical Technology

As the biosimilar regulatory landscape evolves to encourage efficiency and innovation, the commercial landscape is playing catch-up. While the regulatory landscape around biosimilars is evolving to encourage efficiency and innovation, the commercial landscape is playing catch-up as the biosimilar void persists. An expert says the biosimilar commercial landscape must change to close the biosimilar void. Credit: Elma Chowdhury / Shutterstock.com. As the pharmacological treatment landscape continues to evolve, biologics are becoming increasingly incorporated into therapeutic regimens across a broad range of disease areas. When these branded drugs lose their patent exclusivity, some companies develop biosimilars, which can offer a cheaper…

Source: Pharmaceutical Technology